T. Rowe Price Investment Management, Inc. Xencor Inc Transaction History

T. Rowe Price Investment Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$16.53 - $21.42 $40.1 Million - $52 Million	-2,426,996 Reduced 64.23%	1,351,367 $28.7 Million
Q3 2023 Nov 14, 2023	BUY	$20.08 - $25.39 $213,269 - $269,667	10,621 Added 0.28%	3,778,363 $76.1 Million
Q2 2023 Aug 14, 2023	SELL	$24.77 - $29.9 $336,797 - $406,550	-13,597 Reduced 0.36%	3,767,742 $94.1 Million
Q1 2023 May 15, 2023	BUY	$25.95 - $36.95 $1.2 Million - $1.71 Million	46,269 Added 1.24%	3,781,339 $105 Million
Q4 2022 Feb 14, 2023	BUY	$24.79 - $30.86 $23,575 - $29,347	951 Added 0.03%	3,735,070 $97.3 Million
Q3 2022 Nov 14, 2022	BUY	$24.62 - $32.44 $91.9 Million - $121 Million	3,734,119 New	3,734,119 $97 Million

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.44B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.